Nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Bleomycin is a medication primarily used to treat cancer. This includes Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and cervical cancer among others. Typically used with other cancer medications, it can be given intravenously, by injection into a muscle or under the skin. It may also be administered inside the chest to help prevent the recurrence of a pleural effusion due to cancer; however, talc is better for this. It may sometimes be used to treat other difficult-to-treat skin lesions such as plantar warts in immunocompromised patients. Common side effects include fever, weight loss, vomiting, and rash. A severe type of anaphylaxis may occur. It may also cause inflammation of the lungs that can result in lung scarring. Chest X-rays every couple of weeks are recommended to check for this. Bleomycin may cause harm to the baby if used during pregnancy. It is believed to primarily work by preventing the synthesis of DNA. Bleomycin was discovered in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. It is made by the bacterium Streptomyces verticillus.
== Inhibitors == Inhibitors of ALS are used as herbicides that slowly starve affected plants of these amino acids, which eventually leads to inhibition of DNA synthesis. They affect grasses and dicots alike. They are not a chemistry class but rather a mechanism of action class with diverse chemistries. The ALS inhibitor family includes sulfonylureas (SUs), imidazolinones, triazolopyrimidines (see Category:Triazolopyrimidines), pyrimidinyl oxybenzoates, and sulfonylamino carbonyl triazolinones. As of March 2022, the ALS inhibitors suffer the worst (known) resistance problem of all herbicide classes, having 169 known resistant target species. The structures of ALS herbicides are radically different from the normal substrate and so none of them bind at the catalytic site but instead at a site specific to herbicidal action. Therefore resistance mutations are expected to have widely varying effects on normal ALS catalysis activity, positive, negative, and neutral. Unsurprisingly that is exactly what experiments have shown, including Yu et al., 2007 finding resistance in Hordeum murinum due to a proline→serine substitution at amino acid 197 to increase ALS activity by 2x-3x.
However, the results of the 2012 presidential elections gave the PS wins in both districts with a smaller margin in the 7th (Hollande: 51.71% / Sarkozy: 48.29%) than in the 8th (Hollande 64.21% / Sarkozy: 35.79%).
Sources: en.wikipedia.org
In many histological preparations of the submandibular gland, the serous acinar cells located in the hybrid seromucous acini are pushed out from between the mucous acinar cells, and appear as crescent-shaped demilunes located at the back of the acini. This fixation artifact can be avoided by rapid-freezing fixation.
This is based on the beta decay of rubidium-87 to strontium-87, with a half-life of 50 billion years. This scheme is used to date old igneous and metamorphic rocks, and has also been used to date lunar samples. Closure temperatures are so high that they are not a concern. Rubidium-strontium dating is not as precise as the uranium–lead method, with errors of 30 to 50 million years for a 3-billion-year-old sample. Application of in situ analysis (Laser-Ablation ICP-MS) within single mineral grains in faults have shown that the Rb-Sr method can be used to decipher episodes of fault movement.
=== France trip === In June 2026, Peters made a trip to Paris, where he modeled at the Fashion Week opening and attended the Fête de la Musique. Clips from his livestream showing him attempting, without success, to engage with women subsequently went viral in France, drawing ridicule from netizens and French media. Madame Figaro described Peters as being "massively rejected" by Parisian women. Le Monde commented that the "masculinist influencer" who "set out to test his self-proclaimed 'alpha male' magnetism on Parisian women" was "only met with indifference or disdain." In one video, Peters expressed confusion about his lack of success in Paris and theorized that the French women who appeared uninterested in him were probably "lesbians". In later messages, he called the French "impolite shitbags", mocked France's quality of living and stated that European women were less attractive than American ones due to Europe's gene pool being "devastated" in World War II. After Paris, Peters visited the French Riviera. He initially expressed appreciation for Saint-Tropez, but later called the city "retarded". In Cannes, he was denied access to a venue, and heckled in the street by a woman who called him a "Nazi" and told him he was "not welcome" in France.
Sources: en.wikipedia.org
Alfred Fabian Hess, his research associate, stated: "Light equals vitamin D." In 1932, Otto Rosenheim and Harold King published a paper putting forward structures for sterols and bile acids, and soon thereafter collaborated with Kenneth Callow and others on the isolation and characterization of vitamin D. Windaus further clarified the chemical structure of vitamin D. In 1969, a specific binding protein for vitamin D called the vitamin D receptor was identified. Shortly thereafter, the conversion of vitamin D to calcifediol and then to calcitriol, the biologically active form, was confirmed. The photosynthesis of vitamin D3 in skin via previtamin D3 and its subsequent metabolism was described in 1980. The discovery of vitamin D helped to increase the viability and prevalence of intensive animal farming. Prior to its discovery, mortality rates were higher whenever farm animals were moved indoors during winter. Being able to place vitamin D in the feed removed that issue and enabled placing a high number of animals in year-round indoor farming.
=== Inquiries into the paranormal === Jung had an apparent interest in the paranormal and occult. For decades, he attended seances and claimed to have witnessed "parapsychic phenomena". Initially, he attributed these to psychological causes, even delivering a 1919 lecture in England for the Society for Psychical Research on "The Psychological Foundations for the belief in spirits". However, he began to "doubt whether an exclusively psychological approach can do justice to the phenomena in question" and stated that "the spirit hypothesis yields better results". Still, he retained some skepticism toward his own postulation, as he could not find material evidence of the existence of spirits. Jung's ideas about the paranormal culminated in "synchronicity". This is the idea that certain coincidences manifest in the world, have exceptionally intense meaning to observers. Such coincidences have a great effect on the observer from multiple cumulative aspects: from the immediate personal relevance of the coincidence to the observer, from the peculiarities of (the nature of, the character, novelty, curiosity of) any such coincidence; from the sheer improbability of the coincidence, having no apparent causal link (hence Jung's essay subtitle "An Acausal Connecting Principle"). Despite his own experiments failing to confirm the phenomenon he held on to the idea as an explanation for apparent ESP. In addition, he proposed it as a functional explanation for how the I-Ching worked. However, he was never clear about how synchronicity worked.
== Scope and terminology == Traditional packaging protects a product through physical barriers, structural strength, closures, and containment. Passive barrier materials may reduce the movement of oxygen, water vapour, light, aromas, or contaminants without actively changing the internal package environment. A package is normally classified as active when it contains a component designed to absorb, release, or otherwise interact with a substance in the product or package atmosphere. Examples include oxygen scavengers, moisture absorbers, antimicrobial agents, ethylene scavengers, and carbon-dioxide emitters. Vacuum-sealed pouches and low-permeability multilayer films are not automatically active packaging. They remain passive systems unless they are combined with an intentionally reactive or releasing component. Intelligent systems differ from active systems because their main function is to sense, record, display, or communicate information.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.